Syngene International Expands Collaboration with Baxter

12 Sep 2018

Syngene International Ltd., a leading global Contract Research Organization, announced the expansion of the scope of its R&D collaboration with Baxter Healthcare Corporation, a global healthcare company. As part of the expansion, Syngene will set up additional infrastructure at the dedicated Baxter Global Research Center (BGRC) as well as increase the size of its scientific team working on Baxter projects. The duration of the agreement has also been extended until 2024.

Syngene International Expands Collaboration with Baxter

Syngene and Baxter originally established the Baxter Global Research Center, a dedicated R&D center, in 2013.

Mr. Jonathan Hunt, Chief Executive Officer, Syngene International Limited, said, “We are very proud of our work with Baxter and the expansion of our collaboration. We advance excellent science at Syngene and our dedicated R&D Center business model allows us to offer integrated scientific solutions to clients.”

Syngene presently operates dedicated R&D Centers for Bristol-Myers Squibb, Amgen and Herbalife, in addition to Baxter.

About Syngene Syngene International Ltd. (BSE: 539268, NSE: SYNGENE, ISIN: INE398R01022), a global discovery, development and manufacturing organization for novel molecules, provides integrated services to pharmaceutical, biotechnology, nutrition, animal health, consumer goods and specialty chemicals industries across the world. Syngene’s clientele include market leaders like Bristol-Myers Squib, Baxter, Amgen, GSK, Zoetis, Merck KGaA and Herbalife. Its innovative culture is driven by a strong team of over 3500 scientists working with clients to improve R&D productivity, while reducing the development time and cost. For more details, visit www.syngeneintl.com.

Read more